Literature DB >> 20232046

Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models.

Molière Nguile-Makao1, Jean-Ralph Zahar, Adrien Français, Alexis Tabah, Maité Garrouste-Orgeas, Bernard Allaouchiche, Dany Goldgran-Toledano, Elie Azoulay, Christophe Adrie, Samir Jamali, Christophe Clec'h, Bertrand Souweine, Jean-Francois Timsit.   

Abstract

PURPOSE: Methods for estimating the excess mortality attributable to ventilator-associated pneumonia (VAP) should handle VAP as a time-dependent covariate, since the probability of experiencing VAP increases with the time on mechanical ventilation. VAP-attributable mortality (VAP-AM) varies with definitions, case-mix, causative microorganisms, and treatment adequacy. Our objectives here were to compare VAP-AM estimates obtained using a traditional cohort analysis, a multistate progressive disability model, and a matched-cohort analysis; and to compare VAP-AM estimates according to VAP characteristics.
METHODS: We used data from 2,873 mechanically ventilated patients in the Outcomerea database. Among these patients from 12 intensive care units, 434 (15.1%) experienced VAP; of the remaining patients, 1,969 (68.5%) were discharged alive and 470 (16.4%) died. With the multistate model, VAP-AM was 8.1% (95% confidence interval [95%CI], 3.1-13.1%) for 120 days' complete observation, compared to 10.4% (5.6-24.5%) using a matched-cohort approach (2,769 patients) with matching on mechanical ventilation duration followed by conditional logistic regression. VAP-AM was higher in surgical patients and patients with intermediate (but not high) Simplified Acute Physiologic Score II values at ICU admission. VAP-AM was significantly influenced by time to VAP but not by resistance of causative microorganisms. Higher Logistic Organ Dysfunction score at VAP onset dramatically increased VAP-AM (to 31.9% in patients with scores above 7).
CONCLUSION: A multistate model that appropriately handled VAP as a time-dependent event produced lower VAP-AM values than conditional logistic regression. VAP-AM varied widely with case-mix. Disease severity at VAP onset markedly influenced VAP-AM; this may contribute to the variability of previous estimates.

Entities:  

Mesh:

Year:  2010        PMID: 20232046     DOI: 10.1007/s00134-010-1824-6

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  35 in total

1.  The impact of time-dependent bias in proportional hazards modelling.

Authors:  Jan Beyersmann; Martin Wolkewitz; Martin Schumacher
Journal:  Stat Med       Date:  2008-12-30       Impact factor: 2.373

2.  Mortality associated with late-onset pneumonia in the intensive care unit: results of a multi-center cohort study.

Authors:  Pierre Moine; Jean-François Timsit; Arnaud De Lassence; Gilles Troché; Jean-Philippe Fosse; Corrine Alberti; Yves Cohen
Journal:  Intensive Care Med       Date:  2002-01-16       Impact factor: 17.440

3.  Overexpression of the multidrug efflux pumps MexCD-OprJ and MexEF-OprN is associated with a reduction of type III secretion in Pseudomonas aeruginosa.

Authors:  Juan F Linares; Juan A López; Emilio Camafeita; Juan P Albar; Fernando Rojo; Jose L Martínez
Journal:  J Bacteriol       Date:  2005-02       Impact factor: 3.490

4.  Multicenter prospective study of ventilator-associated pneumonia during acute respiratory distress syndrome. Incidence, prognosis, and risk factors. ARDS Study Group.

Authors:  P Markowicz; M Wolff; K Djedaïni; Y Cohen; J Chastre; C Delclaux; J Merrer; B Herman; B Veber; A Fontaine; D Dreyfuss
Journal:  Am J Respir Crit Care Med       Date:  2000-06       Impact factor: 21.405

Review 5.  Ventilator-associated pneumonia.

Authors:  Jean Chastre; Jean-Yves Fagon
Journal:  Am J Respir Crit Care Med       Date:  2002-04-01       Impact factor: 21.405

Review 6.  Ventilator-associated pneumonia and mortality: a systematic review of observational studies.

Authors:  Wilhelmina G Melsen; Maroeska M Rovers; Marc J M Bonten
Journal:  Crit Care Med       Date:  2009-10       Impact factor: 7.598

7.  Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity.

Authors:  Christophe Clec'h; Jean-François Timsit; Arnaud De Lassence; Elie Azoulay; Corinne Alberti; Maite Garrouste-Orgeas; Bruno Mourvilier; Gilles Troche; Muriel Tafflet; Olivier Tuil; Yves Cohen
Journal:  Intensive Care Med       Date:  2004-06-09       Impact factor: 17.440

8.  Influence of nosocomial infection on mortality rate in an intensive care unit.

Authors:  A Bueno-Cavanillas; M Delgado-Rodríguez; A López-Luque; S Schaffino-Cano; R Gálvez-Vargas
Journal:  Crit Care Med       Date:  1994-01       Impact factor: 7.598

9.  Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients.

Authors:  Jean-François Timsit; Jean-Philippe Fosse; Gilles Troché; Arnaud De Lassence; Corinne Alberti; Maïté Garrouste-Orgeas; Caroline Bornstain; Christophe Adrie; Christine Cheval; Sylvie Chevret
Journal:  Crit Care Med       Date:  2002-09       Impact factor: 7.598

10.  Attributable mortality due to nosocomial infections. A simple and useful application of multistate models.

Authors:  M Schumacher; M Wangler; M Wolkewitz; J Beyersmann
Journal:  Methods Inf Med       Date:  2007       Impact factor: 2.176

View more
  44 in total

Review 1.  Update in pulmonary infections 2010.

Authors:  Richard G Wunderink; Grant W Waterer
Journal:  Am J Respir Crit Care Med       Date:  2011-07-15       Impact factor: 21.405

2.  [Hospital-acquired pneumonia].

Authors:  K Tello; M J Richter; W Seeger; M Hecker
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-10-09       Impact factor: 0.840

3.  Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Elizabeth A Lakota; M Courtney Safir; Brian D VanScoy; Yu Nagira; Christopher M Rubino; Nobuo Sato; Tomokazu Koresawa; Kenichiro Kondo; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

4.  Incidence in ICU populations: how to measure and report it?

Authors:  Jan Beyersmann; Petra Gastmeier; Martin Schumacher
Journal:  Intensive Care Med       Date:  2014-05-10       Impact factor: 17.440

5.  Severity of ICU-acquired pneumonia according to infectious microorganisms.

Authors:  Pierre Damas; Nathalie Layios; Laurence Seidel; Monique Nys; Pierrette Melin; Didier Ledoux
Journal:  Intensive Care Med       Date:  2011-05-26       Impact factor: 17.440

6.  A model-based cost-effectiveness analysis of Patient Blood Management.

Authors:  Adina Kleinerüschkamp; Patrick Meybohm; Niels Straub; Kai Zacharowski; Suma Choorapoikayil
Journal:  Blood Transfus       Date:  2018-02-16       Impact factor: 3.443

Review 7.  [Antibiotic treatment of nosocomial pneumonia].

Authors:  S Weiterer; D Störzinger; M Bernhard; K Mayer; C Lass-Flörl; M A Weigand; C Lichtenstern
Journal:  Anaesthesist       Date:  2011-03       Impact factor: 1.041

8.  Azithromycin to prevent Pseudomonas aeruginosa ventilator-associated pneumonia by inhibition of quorum sensing: a randomized controlled trial.

Authors:  Christian van Delden; Thilo Köhler; Françoise Brunner-Ferber; Bruno François; Jean Carlet; Jean-Claude Pechère
Journal:  Intensive Care Med       Date:  2012-04-20       Impact factor: 17.440

9.  Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.

Authors:  Gennaro De Pascale; Serena Fortuna; Mario Tumbarello; Salvatore Lucio Cutuli; MariaSole Vallecoccia; Teresa Spanu; Giuseppe Bello; Luca Montini; Mariano Alberto Pennisi; Pierluigi Navarra; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2014-11-21       Impact factor: 17.440

10.  A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.

Authors:  Samir S Awad; Alejandro H Rodriguez; Yin-Ching Chuang; Zsuszanna Marjanek; Alex J Pareigis; Gilmar Reis; Thomas W L Scheeren; Alejandro S Sánchez; Xin Zhou; Mikaël Saulay; Marc Engelhardt
Journal:  Clin Infect Dis       Date:  2014-04-09       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.